A phase I trial of PRN1008, a novel reversible covalent inhibitor of Bruton's tyrosine kinase, in healthy volunteers

AIM: To evaluate the safety, tolerability, and pharmacokinetics/pharmacodynamics of PRN1008, a novel Bruton's tyrosine kinase (BTK) inhibitor, in healthy volunteers, and thus determine the dose range for future clinical studies. METHODS: This was a two‐part randomized, placebo controlled study...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Br J Clin Pharmacol
Autors principals: Smith, Patrick F., Krishnarajah, Janakan, Nunn, Philip A., Hill, Ron J., Karr, Dane, Tam, D., Masjedizadeh, Mohammad, Funk, Jens O., Gourlay, Steve G.
Format: Artigo
Idioma:Inglês
Publicat: John Wiley and Sons Inc. 2017
Matèries:
Clinical Trials
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5651318/
https://ncbi.nlm.nih.gov/pubmed/28636208
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.13351
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars